Groundbreaking Partnership Aims to Treat Jordan's Syndrome
OSAKA, Japan & SACRAMENTO, Calif.— Shionogi & Co., Ltd., a renowned pharmaceutical company based in Osaka, Japan, has formed a significant collaboration with Jordan’s Guardian Angels. This partnership is marked by a pioneering clinical trial to evaluate a novel investigational drug aimed at combating Jordan's Syndrome, a rare neurodevelopmental disorder.
Exploring Zatolmilast's Potential
The clinical endeavor will be a Phase 2 randomized, double-blind, placebo-controlled study focusing on the drug zatolmilast, specifically targeting PPP2 syndrome type R5D, commonly known as Jordan's Syndrome. This study will assess the drug's safety and tolerability while also aiming to gather pharmacokinetic data and explore preliminary efficacy.
Origins of Zatolmilast
Zatolmilast was originally discovered by Tetra Therapeutics, an innovative company that Shionogi acquired in 2020. The drug’s potential extends beyond Jordan's Syndrome since it is also in trials for Fragile X syndrome, a leading cause of inherited intellectual disabilities, showcasing its versatility.
Community Efforts and Support
Jordan’s Guardian Angels has played a pivotal role in fostering awareness and mobilizing support for research over the past eight years. This advocacy group's efforts are now yielding promising results, with financial backing from California and a collaboration with ten esteemed academic and research institutions. These include Columbia University, Seattle Children’s Hospital, and Boston Children’s Hospital, all working collectively to drive this project forward.
A Message of Hope
Joe Lang, co-founder of Jordan’s Guardian Angels and a parent affected by this syndrome, expressed the profound significance of this trial for families like his. With a diagnosis for his daughter Jordan finally reached after years of uncertainty, he hopes this trial will kindle progress toward effective treatments. Lang emphasizes the trial’s importance as a beacon of hope for children and families impacted by rare diseases.
Trial Details and Participant Eligibility
The Phase 2 study is projected to enlist 30 participants aged 9 to 45 years, all possessing a well-documented diagnosis of the neurodevelopmental disorder. The study will operate on a double-blind basis, involving regular doses of either the investigational drug or a placebo over 24 weeks. Upon completion, participants will also have the chance to partake in an open-label extension for an additional 24 weeks.
The Challenges of Jordan’s Syndrome
Jordan’s Syndrome is characterized by various complications, including developmental delays, seizures, and social challenges similar to those seen in autism. The variability in symptoms makes diagnosis difficult, with whole-exome sequencing often necessary but not universally accessible.
Clinical Innovations and Future Prospects
Dr. Wendy Chung, a leading investigator from Boston Children's Hospital, highlighted the collaboration’s significance in striving for a viable treatment. Her optimism underscores the collaborative efforts with Shionogi, who have a notable legacy in advancing innovative treatments globally.
Regulatory Support and Future Directions
Recently, the FDA awarded zatolmilast the Rare Pediatric Disease Designation, emphasizing its potential in a realm where serious conditions predominantly affect children. This designation also aligns with Shionogi's commitment to addressing unmet medical needs effectively.
The Broader Impact of Research
As part of Shionogi's extensive pipeline, which includes areas like metabolic disorders and oncology, their research into rare diseases reflects a broader commitment to comprehensive healthcare advancements. This project serves not only the specific condition but also illustrates a universal effort to enhance treatment possibilities for various rare diseases.
Frequently Asked Questions
What is Jordan's Syndrome?
Jordan's Syndrome is an ultra-rare genetic neurodevelopmental disorder characterized by developmental delays, cognitive challenges, and various physical symptoms.
What drug is being tested in the study?
The clinical trial is testing zatolmilast, an investigational drug that acts as a selective PDE4D inhibitor.
Who is eligible to participate in the clinical trial?
Participants aged 9 to 45 years with a confirmed diagnosis of PPP2R5D neurodevelopmental disorder are eligible.
How long will the study last?
The study is expected to last approximately 24 weeks, followed by a potential 24-week open-label extension.
What is the significance of the FDA designation?
The FDA's Rare Pediatric Disease Designation for zatolmilast highlights its importance in addressing a serious condition affecting a small patient population.
